Thalassemias (ICD-11: 3A50) - Complete Clinical Coding Guide

1. Introduction

Thalassemias represent a group of hereditary anemias caused by genetic mutations that affect hemoglobin production, the protein responsible for oxygen transport in the blood. These conditions are transmitted in an autosomal recessive manner, meaning that a person needs to inherit defective genes from both parents to develop the complete form of the disease.

The clinical importance of thalassemias cannot be underestimated. These conditions are among the most common genetic diseases worldwide, affecting millions of people, especially in regions where malaria has historically been more prevalent, such as the Mediterranean, Middle East, South Asia, and Southeast Asia. Natural selection favored thalassemia carriers in these regions, as they offered some protection against malaria.

From a public health perspective, thalassemias represent a significant challenge. Patients with severe forms require regular blood transfusions throughout life, iron chelation therapy to prevent iron overload, and continuous multidisciplinary follow-up. The economic and social impact is considerable, affecting not only patients, but also their families and health systems.

Correct coding of thalassemias in ICD-11 is critical for several reasons: it enables appropriate epidemiological tracking of these conditions, facilitates appropriate allocation of health resources, ensures adequate reimbursement for services provided, aids in research on prevalence and clinical outcomes, and ensures that patients receive the necessary specialized follow-up. Diagnostic and coding accuracy is also fundamental for neonatal screening programs and family genetic counseling.

2. Correct ICD-11 Code

Code: 3A50

Description: Thalassemias

Parent category: Anemias or other erythrocyte disorders

Official definition: Disease caused by autosomal recessive genetic mutations leading to abnormal hemoglobin production. This disease is characterized by destruction of red blood cells leading to anemia and abnormal hemoglobin production. This disease may manifest with pallor, jaundice, iron overload, fatigue, or shortness of breath. Confirmation is made by identification of mutations through genetic testing.

Code 3A50 encompasses all forms of thalassemia, including alpha-thalassemia, beta-thalassemia, and their variants. This code is part of the hierarchical structure of ICD-11 that organizes anemias in a more logical and clinically relevant manner. The classification recognizes that thalassemias are qualitative hemoglobin disorders resulting from reduced or absent synthesis of specific globin chains, differentiating them from other structural hemoglobinopathies.

The structure of ICD-11 allows specific subcategories to be added to the main code for greater specificity when necessary, reflecting the specific type of thalassemia, its severity, and particular clinical manifestations. This approach facilitates both clinical documentation and more detailed epidemiological analyses.

3. When to Use This Code

The code 3A50 should be used in specific clinical situations where there is confirmation or strong evidence of thalassemia:

Scenario 1: Diagnosis confirmed by hemoglobin electrophoresis and genetic testing A patient presents with persistent microcytic hypochromic anemia since childhood, with positive family history. Hemoglobin electrophoresis reveals a characteristic pattern of beta-thalassemia minor (thalassemia trait), with hemoglobin A2 elevation above 3.5%. Molecular genetic testing confirms a mutation in the beta-globin gene. This is a clear case for using code 3A50, even in asymptomatic patients or those with mild symptoms.

Scenario 2: Child with beta-thalassemia major in a regular transfusion program A child diagnosed with beta-thalassemia major (Cooley anemia) at 6 months of age, when severe anemia, hepatosplenomegaly, and characteristic bone changes developed. Requires blood transfusions every 2-4 weeks and iron chelation therapy. Code 3A50 is appropriate for all visits related to disease management, including follow-up consultations, hospitalizations for transfusion, and evaluation of complications.

Scenario 3: Prenatal or neonatal diagnosis A fetus identified through prenatal diagnosis as a carrier of alpha-thalassemia major (fetal hydrops due to Bart's hemoglobin), or a newborn detected on neonatal screening with an electrophoretic pattern suggestive of thalassemia. Code 3A50 should be used even before the development of clinical symptoms, as genetic diagnosis confirms the condition.

Scenario 4: Patient with thalassemia intermedia An adolescent with beta-thalassemia intermedia presenting with moderate anemia (hemoglobin between 7-10 g/dL), splenomegaly, and requiring occasional transfusions during infections or surgeries. Not transfusion-dependent as in beta-thalassemia major, but presents with significant clinical manifestations. Code 3A50 adequately captures this intermediate spectrum of the disease.

Scenario 5: Asymptomatic carrier identified on family screening A young adult without clinical symptoms, identified as a carrier of alpha-thalassemia during family investigation after a sibling was diagnosed with thalassemia. Laboratory tests show mild microcytosis with normal or slightly reduced hemoglobin. Genetic testing confirms deletion of two alpha genes. Code 3A50 is appropriate for documenting this important genetic finding for reproductive counseling.

Scenario 6: Complications related to thalassemia An adult patient with beta-thalassemia intermedia developing complications such as leg ulcers, osteoporosis, pulmonary hypertension, or iron overload with endocrine dysfunction. Code 3A50 should be used as the primary diagnosis, with additional codes for specific complications.

4. When NOT to Use This Code

It is essential to distinguish situations where code 3A50 is not appropriate, even when there is anemia or alterations in red blood cells:

Isolated iron deficiency anemia: Patients with microcytic hypochromic anemia due exclusively to iron deficiency, without evidence of thalassemia on electrophoresis or genetic testing, should not receive code 3A50. Although the initial laboratory pattern may be similar, low ferritin and response to iron supplementation distinguish this condition. Use codes for nutritional anemias.

Sickle cell disease and variants: Patients with hemoglobin S (sickle cell disease), hemoglobin C, hemoglobin E, or other structural hemoglobinopathies should not be coded as 3A50, even if they present with hemolytic anemia. These are qualitative hemoglobinopathies with abnormal hemoglobin structure, not quantitative defects in globin chain production. The correct code is 3A51.

Anemia of chronic disease: Patients with anemia secondary to chronic inflammatory conditions, renal diseases, neoplasms, or other systemic conditions should not be coded as thalassemia, even if presenting with microcytosis. Appropriate investigation with electrophoresis and negative family history exclude thalassemia.

Other hereditary hemolytic anemias: Conditions such as hereditary spherocytosis, G6PD deficiency, or paroxysmal nocturnal hemoglobinuria cause hemolysis but are not thalassemias. These conditions have different pathophysiological mechanisms and their own specific codes.

Benign constitutional microcytosis: Some people present with small red blood cells without anemia or identifiable cause, without a thalassemia pattern on specific testing. This is a normal variant that does not require coding as thalassemia.

Combinations with other hemoglobinopathies: When a patient presents with thalassemia associated with sickle cell disease (for example, S/beta-thalassemia), coding may require careful consideration. In some systems, the compound condition may be better represented by specific codes for compound hemoglobinopathies.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

The diagnosis of thalassemia requires a systematic approach combining clinical, laboratory, and genetic findings:

Initial clinical evaluation: Identify signs and symptoms suggestive of thalassemia such as anemia since childhood, pallor, jaundice, splenomegaly, facial bone alterations (in severe forms), growth delay, or positive family history. Investigate the patient's ancestry, as certain populations have higher prevalence.

Complete blood count: Look for microcytic hypochromic anemia with MCV (mean corpuscular volume) disproportionately low relative to the degree of anemia. RDW (red cell distribution width) is usually normal or mildly elevated, unlike iron deficiency anemia. Red blood cell count is often elevated or normal despite anemia.

Hemoglobin electrophoresis: This is the fundamental diagnostic test. In beta-thalassemia minor, there is elevation of hemoglobin A2 (>3.5%) and frequently hemoglobin F. In beta-thalassemia major, there is absence or marked reduction of hemoglobin A with predominance of hemoglobin F. In alpha-thalassemia, patterns vary according to the number of deleted genes.

Molecular genetic testing: Definitive confirmation comes from identification of specific mutations in globin genes through techniques such as PCR, genetic sequencing, or deletion analysis. This test is especially important for genetic counseling and prenatal diagnosis.

Iron studies: Assess ferritin, transferrin saturation, and serum iron to exclude concomitant iron deficiency and monitor iron overload in transfused patients.

Step 2: Verify specifiers

After confirming the diagnosis of thalassemia, determine the specific characteristics:

Type of thalassemia: Identify whether it is alpha-thalassemia (deletions or mutations in HBA1 and HBA2 genes) or beta-thalassemia (mutations in HBB gene). This influences prognosis and management.

Clinical severity: Classify as thalassemia major (transfusion-dependent, severe symptoms since childhood), thalassemia intermedia (moderate anemia, occasional transfusions), or thalassemia minor/thalassemia trait (asymptomatic or minimal symptoms).

Carrier status: Determine whether the patient is homozygous (two copies of the mutated gene), compound heterozygous (two different mutations), or simple heterozygous (carrier).

Present complications: Document complications such as iron overload, endocrine dysfunction, osteoporosis, pulmonary hypertension, leg ulcers, gallstones, or other manifestations requiring additional codes.

Step 3: Differentiate from other codes

Nutritional or metabolic anemias: The main difference lies in etiology. Nutritional anemias result from deficiency of iron, vitamin B12, folate, or other nutrients, while thalassemias are genetic defects in globin synthesis. Hemoglobin electrophoresis is normal in pure nutritional anemias. Response to nutritional supplementation corrects nutritional anemias but not thalassemias.

Hemolytic anemias: Although thalassemias cause hemolysis, this broader code includes multiple causes of increased red blood cell destruction (autoimmune, mechanical, enzymatic, membrane-related). Use 3A50 specifically when the hemolytic mechanism is secondary to genetically confirmed thalassemia, not for other causes of hemolysis.

3A51 - Sickle cell disease and other hemoglobinopathies: The fundamental difference is that thalassemias (3A50) are quantitative defects (reduced production of normal globin chains), while 3A51 includes qualitative defects (production of structurally abnormal globin chains such as hemoglobin S, C, E). Electrophoresis clearly differentiates: thalassemias show abnormal proportions of normal hemoglobins, while structural hemoglobinopathies show variant hemoglobins. Cases of S/beta-thalassemia may require special consideration in coding.

Step 4: Required documentation

For appropriate coding of 3A50, medical documentation must include:

Mandatory checklist:

Specific type of thalassemia (alpha or beta)
Severity (major, intermedia, minor/trait)
Hemoglobin electrophoresis results with specific values
Genetic testing performed and mutations identified
Family history of thalassemia or anemia
Complete blood count with red cell indices
Transfusion requirement (frequency if applicable)
Iron chelation therapy (if in use)
Present complications and their management
Ancestry/ethnic origin when relevant

Adequate documentation: Documentation must be sufficiently detailed to justify the code, including diagnostic reasoning, confirmatory tests, and therapeutic plan. Regular updates on clinical evolution, treatment response, and new complications are essential for continuity of care.

6. Complete Practical Example

Clinical Case

Initial presentation: Sofia, 8 months old, is brought to pediatric consultation for progressive pallor and irritability over the last 6 weeks. Parents report that the child was well until 4-5 months of age, when she began to become paler and less active. There is no history of bleeding, diarrhea, or other illnesses. The mother mentions that she and the father are from a Mediterranean region and that some family members have "anemia since forever."

Physical examination: Pale child (blanched mucous membranes ++/4+), mild jaundice (icterus +/4+), irritable but consolable. Weight and height at the 10th percentile (previously was at the 25th percentile). Cardiac auscultation reveals a 2+/6+ systolic murmur at the mitral focus. Abdomen with palpable liver 3 cm below the right costal margin and palpable spleen 4 cm below the left costal margin. No other significant abnormalities.

Evaluation performed:

Initial complete blood count showed:

Hemoglobin: 6.2 g/dL (normal for age: 11-13 g/dL)
Hematocrit: 19%
MCV: 58 fL (normal for age: 70-84 fL)
MCH: 18 pg (normal for age: 23-31 pg)
RDW: 18% (mildly elevated)
Red blood cell count: 4.8 million/mm³ (elevated for the degree of anemia)
White blood cells and platelets: normal

Iron studies:

Serum iron: 95 mcg/dL (normal)
Ferritin: 180 ng/mL (elevated for age)
Transferrin saturation: 45% (normal/elevated)

Hemoglobin electrophoresis:

Hemoglobin F: 85% (markedly elevated)
Hemoglobin A2: 3%
Hemoglobin A: 12% (reduced)

Peripheral blood smear: Marked anisocytosis, microcytosis, hypochromia, target cells, nucleated erythrocytes, basophilic stippling.

Molecular genetic testing: Mutations identified in the HBB gene in homozygosity (beta-0-thalassemia), confirming beta-thalassemia major.

Diagnostic reasoning: The presentation of severe microcytic hypochromic anemia in an infant of Mediterranean ancestry, with hepatosplenomegaly, iron overload (elevated ferritin without prior transfusions due to hemolysis and ineffective erythropoiesis), electrophoresis showing marked elevation of hemoglobin F with reduction of hemoglobin A, and genetic confirmation of homozygous mutations in the beta-globin gene, definitively establish the diagnosis of beta-thalassemia major (Cooley anemia).

The positive family history and Mediterranean ancestry increase the pretest probability. Exclusion of iron deficiency (elevated ferritin, normal transferrin saturation) is important, as iron deficiency anemia is a common differential diagnosis in infants. The severity of anemia, early hepatosplenomegaly, and electrophoretic pattern are characteristic of thalassemia major, not thalassemia trait.

Coding justification: This case meets all criteria for code 3A50:

Genetic confirmation of mutations in the beta-globin gene
Compatible clinical manifestations (severe anemia, pallor, jaundice, hepatosplenomegaly)
Characteristic laboratory pattern (microcytic hypochromic anemia with typical electrophoresis)
Exclusion of other causes of anemia
Family history and ancestry consistent

Step-by-Step Coding

Criteria analysis:

Confirmed anemia: Hemoglobin 6.2 g/dL (severe)
Microcytosis and hypochromia: MCV 58 fL, MCH 18 pg
Diagnostic electrophoresis: HbF 85%, HbA reduced
Genetic confirmation: HBB mutations in homozygosity
Clinical manifestations: Hepatosplenomegaly, jaundice

Code selected: 3A50 - Thalassemias

Complete justification: Code 3A50 is appropriate because it precisely represents the diagnosed condition: genetically confirmed thalassemia with significant clinical manifestations. We do not use codes for unspecified anemia because we have a definitive etiologic diagnosis. We do not use code for structural hemoglobinopathies (3A51) because there is no variant hemoglobin, only reduced production of normal beta chains.

Applicable complementary codes:

Code for splenomegaly (if separate coding of manifestations is necessary)
Code for iron overload (when it develops, in future follow-up)
Codes for specific complications that may arise (endocrinopathies, osteoporosis, etc.)
Code for transfusion dependency (when applicable in the coding system)

Documented management plan:

Initiation of regular transfusion program
Iron chelation therapy when appropriate
Multidisciplinary follow-up (hematology, cardiology, endocrinology)
Family genetic counseling
Evaluation for possible bone marrow transplantation

7. Related Codes and Differentiation

Within the Same Category

Nutritional or metabolic anemias vs. 3A50:

Use nutritional anemias when the cause of anemia is iron deficiency, vitamin B12, folate, or other essential nutrient deficiency. The main difference lies in etiology: acquired deficiency versus hereditary genetic defect. Laboratory findings in nutritional anemias show normal hemoglobin electrophoresis, low ferritin (in iron deficiency), low B12 or folate levels (in megaloblastic anemias), and response to appropriate supplementation.

Use 3A50 when there is genetic confirmation or strong evidence of thalassemia through characteristic electrophoresis, positive family history, and lack of response to nutritional supplementation. Microcytosis in thalassemia is disproportionate to the degree of anemia, and red blood cell count is usually elevated, unlike iron deficiency anemia where the count is reduced.

Hemolytic anemias vs. 3A50:

Hemolytic anemias is a broad category including multiple causes of increased red blood cell destruction: autoimmune, microangiopathic, membrane defects (spherocytosis), enzymatic (G6PD deficiency), mechanical (cardiac valves), among others.

Use specific hemolytic anemia codes when hemolysis has a cause different from thalassemia, such as autoimmune hemolytic anemia (positive Coombs test), hereditary spherocytosis (spherocytes on blood smear, altered osmotic fragility test), or G6PD deficiency (history of hemolysis after exposure to oxidants).

Use 3A50 when hemolysis is secondary to thalassemia. Although thalassemias cause hemolysis (through destruction of defective red blood cells), code 3A50 is more specific and clinically relevant, capturing the underlying genetic etiology.

3A51 - Sickle cell disease and other hemoglobinopathies vs. 3A50:

This is the most important differentiation. Code 3A51 is used for structural hemoglobinopathies where there is production of abnormal globin chains: sickle cell disease (HbS), hemoglobin C, hemoglobin E, hemoglobin D, among other structural variants.

The main difference is pathophysiological:

3A50 (Thalassemias): Quantitative defect - reduced or absent production of structurally normal globin chains (alpha or beta)
3A51 (Structural hemoglobinopathies): Qualitative defect - production of globin chains with altered amino acid sequence

On hemoglobin electrophoresis:

Thalassemias (3A50): Abnormal proportions of normal hemoglobins (A, A2, F)
Structural hemoglobinopathies (3A51): Presence of variant hemoglobins (S, C, E, etc.)

Special situation: Patients with compound conditions such as S/beta-thalassemia (inherit HbS gene from one parent and beta-thalassemia gene from the other) present features of both conditions. Coding may vary according to local guidelines, but frequently the predominant clinical phenotype guides the choice of primary code.

Differential Diagnoses

Anemia of chronic disease: May present with mild microcytosis, but usually with elevated ferritin, low transferrin saturation, and normal electrophoresis. History of underlying inflammatory, infectious, or neoplastic disease.

Lead poisoning: Can cause microcytic anemia with basophilic stippling, but there is history of exposure, elevated blood lead levels, and normal electrophoresis.

Sideroblastic anemia: May present with microcytosis, but is characterized by ring sideroblasts in bone marrow, a finding absent in thalassemias.

Myelodysplastic syndrome: May have anemia with microcytosis, but usually in older patients, with multiple cytopenias and dysplastic changes in bone marrow.

8. Differences with ICD-10

In ICD-10, thalassemias were coded primarily as:

D56: Thalassemia
- D56.0: Alpha thalassemia
- D56.1: Beta thalassemia
- D56.2: Delta-beta thalassemia
- D56.3: Thalassemia trait
- D56.4: Hereditary persistence of fetal hemoglobin
- D56.8: Other thalassemias
- D56.9: Thalassemia, unspecified

Main changes in ICD-11:

The transition to code 3A50 in ICD-11 represents a significant structural reorganization. The alphanumeric system was completely reformulated, with codes starting with numbers followed by letters, different from the letter-number pattern of ICD-10.

ICD-11 offers greater flexibility through a post-coordination system, allowing detailed specifiers to be added to the base code without necessarily creating separate subcodes. This allows more granular documentation of features such as severity, specific type of mutation, and associated complications.

The hierarchical structure was improved, with more logical grouping of related conditions. Thalassemias remain clearly separated from structural hemoglobinopathies, better reflecting distinct pathophysiology.

Practical impact of these changes:

For healthcare professionals, the main change is becoming familiar with the new code 3A50 instead of the D56.x codes. Electronic medical record systems will need to be updated to include the new codes.

The greater specificity possible through post-coordination allows richer documentation, facilitating epidemiological research, clinical outcomes studies, and quality of care analyses. However, this requires adequate training to ensure correct use of specifiers.

For health management and reimbursement, the transition may require mapping between ICD-10 and ICD-11 codes during the adaptation period, especially in systems where different institutions may be at different implementation phases.

Clarity in differentiating between thalassemias and other hemoglobinopathies can improve diagnostic accuracy and reduce coding errors, benefiting both individual care and population health.

9. Frequently Asked Questions

1. How is thalassemia diagnosed?

The diagnosis of thalassemia involves multiple steps. Initially, a complete blood count may reveal microcytic hypochromic anemia with normal or elevated red blood cell count, suggesting thalassemia rather than iron deficiency. The fundamental diagnostic test is hemoglobin electrophoresis, which shows characteristic patterns: in beta-thalassemia minor, there is elevation of hemoglobin A2 above 3.5%; in beta-thalassemia major, there is absence or marked reduction of hemoglobin A with predominance of hemoglobin F. Definitive confirmation comes from molecular genetic testing that identifies specific mutations in the globin genes. Positive family history and ancestry from regions of high prevalence increase clinical suspicion.

2. Is treatment available in public health systems?

The availability of treatment for thalassemia in public health systems varies according to region and local resources. Essential components of treatment include regular blood transfusions (for beta-thalassemia major), iron chelation therapy to prevent iron overload, folic acid supplementation, and monitoring of complications. Many public health systems offer these treatments, especially in regions with high prevalence of thalassemia where specific programs have been established. More advanced therapies such as hematopoietic stem cell transplantation or gene therapy have more limited availability and generally require specialized centers. Patients should consult their local health services about available programs for chronic hematological diseases.

3. How long does treatment last?

For beta-thalassemia major, treatment is lifelong. Patients require regular blood transfusions (usually every 2-4 weeks) indefinitely to maintain adequate hemoglobin levels. Iron chelation therapy is also continuous while the patient receives transfusions, as iron overload occurs progressively. Monitoring of complications (cardiac, endocrine, hepatic, bone) is necessary throughout life. For beta-thalassemia intermediaria, treatment may be less intensive but still requires prolonged follow-up. Only curative interventions such as successful hematopoietic stem cell transplantation or gene therapy can potentially eliminate the need for continuous treatment. Asymptomatic carriers (beta-thalassemia minor) generally do not require specific treatment, but benefit from genetic counseling.

4. Can this code be used in medical certificates?

Yes, code 3A50 can and should be used in official medical documentation, including certificates when appropriate. However, use in certificates depends on the purpose of the document. For certificates of absence from work or school due to complications of thalassemia (infections during periods of immunosuppression, hospitalizations for transfusion, treatment of complications), the code is appropriate. For documentation of chronic condition in requests for benefits, workplace or school accommodations, or justifications for regular medical follow-up, the code is also pertinent. The inclusion of the specific code increases documentation accuracy and facilitates administrative processes. Professionals should consider confidentiality issues and include only information necessary for the specific purpose of the certificate.

5. Do carriers of beta-thalassemia minor need treatment?

Carriers of beta-thalassemia minor (thalassemia trait) are generally asymptomatic or present with very mild symptoms and do not require specific treatment for the condition. Anemia, when present, is generally mild and well tolerated. The most important aspect for carriers is genetic counseling, especially before family planning. If both parents are carriers, there is a 25% chance that each child will have beta-thalassemia major. Carriers should avoid unnecessary iron supplementation, as they do not have iron deficiency and supplementation can cause overload. During pregnancy, serious infections, or surgery, carriers may require closer monitoring. The main intervention is education about the condition, genetic implications, and identification of carrier partners for appropriate preconception counseling.

6. Can thalassemia be cured?

Currently, hematopoietic stem cell transplantation (bone marrow transplant) is the only established curative option for beta-thalassemia major. When successful, it can eliminate the need for transfusions and chelation therapy. However, the procedure has significant risks and requires a compatible donor, being more commonly performed in children. Experimental gene therapies are showing promising results in clinical trials, offering hope of cure without the need for a donor. These therapies involve genetic modification of the patient's own cells to correct the defect in globin production. Although not yet widely available, they represent an important advance. For most patients currently, treatment remains supportive (transfusions and chelation), focusing on maintaining quality of life and preventing complications.

7. Can children with thalassemia attend school normally?

Children with beta-thalassemia minor generally have no restrictions and can fully participate in school activities. For children with beta-thalassemia major or intermediaria, school attendance is generally possible but may require some adaptations. Periodic absences for transfusions or medical appointments should be anticipated and communicated to the school. During periods of more pronounced anemia (before scheduled transfusions), the child may have lower tolerance for intense exercise. Educators should be informed about the condition to recognize signs of complications (marked pallor, extreme fatigue, jaundice) and facilitate communication with family. With appropriate management, many children with thalassemia have normal school performance. Psychosocial support can be beneficial for dealing with emotional aspects of having a chronic condition.

8. Is there a relationship between thalassemia and COVID-19?

Patients with thalassemia, especially those with beta-thalassemia major in regular transfusion programs, were considered a risk group during the COVID-19 pandemic. Splenectomy (performed in some patients) may increase the risk of serious infections. Iron overload and cardiac or pulmonary complications may worsen COVID-19 outcomes. Recommendations included prioritization for vaccination, careful continuity of transfusions and chelation (with adaptations to reduce exposure when possible), and rigorous monitoring if infected. Studies showed that well-managed thalassemia patients do not necessarily have worse outcomes than the general population, but those with significant complications require additional care. Complete vaccination and preventive measures remain important for this group.

Conclusion

The ICD-11 code 3A50 for thalassemias represents an essential tool for accurate documentation of this important hereditary hematological condition. Appropriate coding requires understanding of pathophysiology, diagnostic criteria, differentiation of similar conditions, and appropriate documentation. With the detailed knowledge presented in this guide, health professionals can ensure accurate coding that benefits both individual care and population health through improved epidemiological tracking and resource allocation.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Thalassemias

Partager